Benign Prostatic Hyperplasia (BPH) & Lower Urinary Tract Symptoms: 2026 Treatment Guide

What Is BPH, and Why Does It Cause So Many Urinary Symptoms?

The prostate gland sits directly beneath the bladder, and the urethra — the tube that carries urine out of the body — passes straight through its center. When the prostate enlarges, it can squeeze the urethra, making urination more difficult, slower, and incomplete. That mechanical reality is the core of what makes BPH so disruptive to daily life.

BPH stands for benign prostatic hyperplasia — a condition in which the glandular and stromal tissue within the prostate's transition zone proliferates in a non-cancerous way.^[1] The key word is benign: BPH is not cancer, does not increase cancer risk, and does not transform into cancer. The term LUTS — lower urinary tract symptoms — describes the collection of voiding and storage problems that enlarged or overactive bladder conditions can produce, BPH being the most common cause in older men.

The prostate goes through two major growth phases in a man's life. The first occurs during puberty. The second begins around age 25 and continues throughout life — meaning every man's prostate grows slowly over decades.^[5] Whether that growth produces symptoms depends on anatomy, the degree of bladder involvement, and individual variation. Some men with significantly enlarged prostates have minimal symptoms; others with modest enlargement have severely disrupted lives. Prostate size alone does not determine symptom severity.

BPH affects 5–6% of men ages 40–64 and 29–33% of men ages 65 and older.^[5] Among men older than 50, it is the most common prostate condition. The condition rarely produces symptoms before age 40, but the groundwork is laid well before symptoms appear.

What Causes BPH and Lower Urinary Tract Symptoms

The exact trigger for pathologic prostate growth is not fully understood. What is known is that age-related changes in sex hormone balance drive the process. As men age, total testosterone levels decline while relative estrogen levels rise. Dihydrotestosterone (DHT) — converted from testosterone by the enzyme 5-alpha reductase — remains active in prostate tissue and continues to stimulate cellular growth. This is why drugs that block 5-alpha reductase (finasteride and dutasteride) can shrink the prostate over time.

Within the prostate, the growth occurs primarily in the transition zone — the inner portion of the gland immediately surrounding the urethra. As this zone expands, it creates a ring of pressure around the urethra, producing what is called bladder outlet obstruction. The bladder has to work harder to push urine through a narrowed channel, which leads first to bladder wall thickening (detrusor hypertrophy) and eventually to changes in bladder function.

The bladder's response to obstruction partly explains why BPH produces two distinct symptom categories. Obstruction of the urethra produces voiding (obstructive) symptoms. The bladder's compensatory hyperactivity produces storage (irritative) symptoms. Over time, an overworked bladder can lose its ability to contract effectively, leading to chronic urinary retention and post-void residual urine that creates a reservoir for urinary tract infections.

Risk Factors

Age is the single strongest predictor. Beyond that, research has identified several modifiable and non-modifiable contributors:^[5][7]

• Family history: A first-degree relative with BPH increases your risk meaningfully.
• Metabolic syndrome: Obesity, type 2 diabetes, and elevated triglycerides are each associated with higher BPH risk and more severe symptoms.
• Cardiovascular disease: Studies show an association between heart disease and BPH progression, though the mechanism is not fully established.
• Sedentary lifestyle: Physical inactivity consistently increases risk; regular exercise appears protective.
• Hypertension: Linked to higher LUTS severity, possibly through shared vascular pathways.
• Erectile dysfunction (ED): BPH and ED frequently coexist; both conditions reflect age-related changes in the prostate, bladder, and surrounding smooth muscle.

What does not cause BPH: prostate cancer, sexual activity, diet (no specific dietary pattern has been shown to cause or prevent BPH, though certain lifestyle changes can reduce symptom severity).

Symptoms: Obstructive vs. Irritative, and the IPSS Scale

BPH symptoms fall into two categories, and understanding the difference matters because treatment approaches can differ depending on which type predominates.

Obstructive (voiding) symptoms reflect the mechanical effect of the enlarged prostate compressing the urethra:

• Weak or intermittent urine stream
• Hesitancy — difficulty getting the stream started
• Straining to void
• Post-void dribbling
• Sensation of incomplete bladder emptying
• Urinary retention (partial or, in severe cases, complete)

Irritative (storage) symptoms reflect bladder dysfunction — urgency, frequency, and nocturia that arise from the overworked, hyperactive bladder:

• Urinary urgency (sudden, difficult-to-delay urge to urinate)
• Frequency (urinating more than 8 times per day)
• Nocturia (waking at least twice per night to urinate)
• Urgency incontinence (leakage before reaching the toilet)

Clinicians use the International Prostate Symptom Score (IPSS) — a validated 7-question questionnaire — to measure symptom severity at baseline and track response to treatment.^[7] Scores range from 0 to 35: mild (0–7), moderate (8–19), and severe (20–35). The IPSS is the only urinary symptom score shown to significantly predict the risk of acute urinary retention. An IPSS of 8 or higher generally suggests treatment is worth discussing; a score of 20 or higher indicates severe impact on quality of life.

What's Changed: The 2026 AUA Guideline Update

The American Urological Association released its updated BPH/LUTS guideline on May 7, 2026 — a significant revision that replaces the 2023 version and incorporates evidence from a systematic review current through January 2025, with supplemental searches completed December 15, 2025.^[4] The update includes 62 recommendations organized across three publications.

Key Updates in Evaluation

PSA testing is now explicitly framed as a shared decision-making conversation rather than a default evaluation step. Uroflowmetry and post-void residual measurement "may be used" — giving clinicians and patients flexibility while acknowledging these tests add value when the clinical picture is unclear. The guideline introduces a 6-month re-evaluation milestone for patients on medical therapy, providing a structured checkpoint to assess whether treatment is working before escalating.

Key Updates in Medical Management

Uroselective alpha blockers remain first-line therapy. The 2026 guideline specifically names silodosin, alfuzosin, and tamsulosin as the preferred uroselective agents. Tadalafil 5 mg daily is endorsed not just for men with coexisting LUTS and ED, but also as a monotherapy alternative for those who prefer it. A notable addition: tadalafil 5 mg may now be combined with a 5-ARI for select patients — supported by 2024 randomized trial data showing comparable urinary symptom improvement with the added benefit of better sexual function outcomes compared to tamsulosin plus a 5-ARI.^[12]

On the question of cancer risk during active surveillance: the 2026 guideline clarifies that 5-ARI therapy does not increase prostate cancer progression in men on active surveillance — a clinically meaningful statement that had previously been a source of uncertainty for patients managing both BPH and low-grade prostate cancer simultaneously.

Key Updates in Procedural Management

Two procedural changes stand out. Prostate artery embolization (PAE) was upgraded from Grade C to Grade B evidence — a recognition that years of randomized trial data have established PAE as a legitimate option for prostates ≥50 cc, including patients on anticoagulation who are at higher bleeding risk from conventional surgery.^[10] PAE now joins HoLEP, thulium laser enucleation (ThuLEP), and photoselective vaporization (PVP) as recommended options for anticoagulated patients.

Aquablation therapy — robotic waterjet resection — saw its evidence strengthened for the 80–150 mL prostate size range, extending beyond its previous strongest evidence base of 30–80 mL. Five-year data from the WATER II trial, published in the Journal of Urology, showed durable efficacy and low retreatment rates in men with large prostates.^[11]

HIFU (high-intensity focused ultrasound) and cryoablation are explicitly not recommended outside of clinical trials — an important boundary for patients who may have encountered these options in non-academic settings.

The Decision Framework: When to Treat, When to Refer

Not every man with BPH symptoms needs treatment. The decision to initiate therapy — and which therapy — depends on three inputs: symptom severity (IPSS score), degree of bother, and clinical findings. A man with an IPSS of 5 who finds his symptoms mildly inconvenient is a different clinical scenario from a man with an IPSS of 22 who is waking four times per night.

The general framework works like this:

An important nuance in evaluation: prostate size must be established before prescribing a 5-ARI. The AUA recommends transrectal ultrasound (TRUS) to measure prostate volume accurately before initiating finasteride or dutasteride, or before surgical planning.^[7] Digital rectal exam is useful but reliably identifies only prostates larger than 50 mL — it can miss smaller-but-still-significant enlargement.

Men who have primarily storage symptoms (urgency, frequency, nocturia) that do not respond to alpha blockers may have a concurrent overactive bladder component requiring separate evaluation. The differential diagnosis for LUTS is broad — bladder dysfunction, urethral stricture, neurogenic disorders, UTI, and prostate or bladder cancer can all produce similar symptoms. A thorough history and urinalysis help sort through this before treatment is started.

Treatment Options: A Full Review

Lifestyle and Behavioral Modifications

These are the starting point for mild symptoms and a supplement to medication at all severity levels. Evidence supports meaningful symptom reduction from behavioral changes alone — without the side effects of medication.

• Fluid management: Limit total fluid intake, especially in the 2–3 hours before bed or before outings where bathroom access is limited.
• Reduce caffeine and alcohol: Both increase urinary frequency and bladder irritability.
• Bladder training: Scheduled voiding every 2–3 hours and urge suppression techniques (pelvic floor contraction when urgency strikes) can reduce storage symptoms significantly.
• Double voiding: Urinating, relaxing for a moment, then urinating again — helps empty the bladder more completely.
• Physical activity: Regular exercise reduces symptom progression risk. Sedentary behavior is an independent risk factor for worsening LUTS.
• Medication review: Decongestants, antihistamines, tricyclic antidepressants, and diuretics can all worsen BPH symptoms and may be modifiable.

Alpha Blockers (Uroselective Agents)

The most commonly prescribed first-line medications for BPH-related LUTS work by relaxing smooth muscle in the bladder neck and prostate, widening the urethral channel without changing prostate size. Relief is fast — most men notice improvement within 24–48 hours. Based on a meta-analysis of 19 randomized controlled trials involving nearly 10,000 participants, all alpha blockers produce consistent symptom improvement over placebo.^[7]

The 2026 AUA guideline favors the uroselective agents:

• Tamsulosin (Flomax): 0.4 mg once daily after meals; the most widely prescribed agent. Side effects include ejaculatory dysfunction and dizziness.
• Silodosin (Rapaflo): 8 mg once daily; highest alpha-1A selectivity; effective but associated with the highest rate of ejaculatory dysfunction in the class.
• Alfuzosin (Uroxatral): 10 mg extended-release once daily; notably lower ejaculatory dysfunction rate than tamsulosin or silodosin.

Important safety note: alpha blockers increase the risk of floppy iris syndrome (IFIS) during cataract surgery. If cataract surgery is being considered, alpha blockers should not be started until after ophthalmologic evaluation, and the ophthalmologist must be informed if a patient is already taking one.^[7]

5-Alpha Reductase Inhibitors (5-ARIs)

Finasteride (Proscar, 5 mg daily) and dutasteride (Avodart, 0.5 mg daily) work by blocking the enzyme that converts testosterone to DHT — the primary driver of prostatic growth. Over 6–12 months, they shrink the prostate by about 20–25%, improving urine flow and reducing long-term risk of urinary retention and the need for surgery.^[7]

These agents are indicated when prostate volume is ≥30 mL (or when PSA exceeds 1.5 ng/mL as a proxy for size). They are not fast — at one year or less, combination therapy with an alpha blocker is no more effective than an alpha blocker alone. Beyond one year, the combination consistently outperforms either agent individually.

PSA is reduced by approximately 50% during 5-ARI therapy. This means a PSA result must be doubled for cancer screening purposes when interpreting lab values in men on these drugs. The 2026 AUA guideline confirms that 5-ARIs do not increase prostate cancer progression in men on active surveillance — a finding that removes a barrier that had previously made some patients hesitant to use them.

Tadalafil 5 mg Daily (PDE5 Inhibitor)

Tadalafil — the same molecule used at higher doses for erectile dysfunction — works at 5 mg daily by blocking PDE5, increasing cGMP levels and relaxing smooth muscle throughout the bladder, prostate, and urethra. A Cochrane review of four randomized controlled trials (933 participants) found tadalafil similarly effective to alpha blockers for LUTS improvement.^[8]

Tadalafil is the first-choice option when ED and LUTS coexist — it addresses both conditions with a single daily medication. Per the 2026 guideline, it can be combined with a 5-ARI for men who need prostate shrinkage and wish to avoid or cannot tolerate alpha blockers. One important contraindication: tadalafil must not be combined with non-selective alpha blockers (doxazosin, terazosin) due to the risk of severe hypotension.

Beta-3 Agonist (Mirabegron) and Anticholinergics

When storage symptoms dominate — urgency, frequency, nocturia — and prostate-focused medications haven't fully addressed them, bladder-targeted agents may be added. Mirabegron (Myrbetriq) relaxes the bladder during filling via beta-3 receptor agonism; it carries less urinary retention risk than anticholinergics and is preferred in older men. Anticholinergics (oxybutynin, tolterodine, solifenacin) work but require caution: they can precipitate urinary retention (especially when PVR exceeds 250–300 mL) and are associated with cognitive side effects and increased dementia risk in older patients.^[7]

Combination Therapy

The most established combination is an alpha blocker plus a 5-ARI — recommended for men with moderate-to-severe symptoms and a prostate volume ≥30 mL. Dutasteride plus tamsulosin (available as Jalyn) is the most studied combination. The 2024 tadalafil/finasteride versus tamsulosin/finasteride trial (n=100) showed both regimens produced comparable IPSS improvements at three months, with the tadalafil combination offering better sexual function outcomes.^[12]

Procedural Options — Evidence Summary

What Telehealth Can Do — and Cannot

BPH management involves two distinct pathways, and understanding which belongs to telehealth and which belongs in a clinic or operating room helps you plan your care efficiently.

What Works Well via Telehealth

The initial clinical conversation — history-taking, IPSS administration, and shared decision-making — can happen productively through a video visit. Lifestyle counseling (fluid management strategies, caffeine and alcohol reduction, bladder training techniques) is fully telehealth-compatible. Prescribing uroselective alpha blockers — tamsulosin, silodosin, alfuzosin — is appropriate remotely when there are no contraindications identified by history.

Tadalafil 5 mg daily for the LUTS and ED overlap population is another area where telehealth fits well. Monitoring 5-ARI therapy — after an initial in-person prostate sizing has been done — can continue via telehealth, including reviewing the PSA interpretation adjustment these drugs require. The 6-month reassessment visit recommended by the 2026 AUA guideline for patients on medical therapy is well-suited to a video appointment when no new procedural evaluation is warranted.^[2]

What Requires an In-Person Visit

Several critical diagnostic elements cannot be performed remotely:

• Digital rectal exam (DRE): Assesses prostate size, consistency, and any concerning nodules; required as part of a complete BPH evaluation.
• PSA blood draw: Must be done at a laboratory; results can then be reviewed via telehealth.
• Uroflowmetry: Measures peak urinary flow rate (Qmax) — a key metric for obstruction severity.
• Post-void residual (PVR) measurement: Performed by bladder ultrasound or catheterization; essential before adding anticholinergics or in suspected retention.
• Transrectal ultrasound (TRUS): Required for accurate prostate volume measurement before starting 5-ARIs or planning procedures.
• Urodynamic studies (UDS): For complex cases with possible neurogenic components or pre-surgical planning.
• Cystoscopy: For evaluation of hematuria, suspected stricture, or pre-procedural assessment.
• All procedural interventions: PAE, Aquablation, TURP, HoLEP, UroLift, Rezum — all require specialized facilities.

A practical care model for many patients: telehealth handles the first visit, lifestyle counseling, alpha blocker initiation, and follow-up monitoring. In-person visits handle the physical exam, labs, imaging, and any procedures. These two pathways work together — neither replaces the other.

Red Flags: When to Skip Telehealth and Get Urgent Care

Acute urinary retention deserves emphasis. The 2026 AUA guideline specifically recommends initiating an alpha blocker immediately at the time of urethral catheterization, then attempting a trial without catheter (TWOC) after three days.^[1] This approach — rather than waiting and watching — has been shown to improve the odds of successful voiding after retention. It is not something telehealth can manage, but it is something a telehealth physician can help identify and direct you toward appropriately.

Frequently Asked Questions

Bottom Line

BPH and LUTS affect the majority of men as they age — but most cases can be managed effectively without surgery. The 2026 AUA guideline update gives clinicians clearer, more current tools: shared decision-making on PSA testing, a structured 6-month reassessment milestone, upgraded evidence for PAE, expanded Aquablation evidence, and explicit endorsement of the tadalafil-plus-5-ARI combination for the right patient.

The practical takeaway is this: if you have urinary symptoms that are affecting your sleep, your daily activities, or your quality of life — start with a conversation. That first conversation can happen via telehealth in many cases. What follows — the physical exam, imaging, labs, procedures — will determine the full picture and the right treatment path. Neither telehealth nor in-person care alone covers the full spectrum of BPH management. Together, they do.

Current evidence supports a stepwise, patient-centered approach: lifestyle first, uroselective alpha blockers or tadalafil for moderate symptoms, 5-ARI added when the prostate is large enough to warrant shrinkage, and procedural options reserved for those who fail medical therapy or develop complications. That framework is now better defined than it has ever been.